Viking Therapeutics, Inc. Aktie News

A $1,000 investment can be an ideal amount to invest in an up-and-coming growth stock. The stocks below are still modest in size, with market capitalization of less than $6 billion.

Takeover activity has been high lately in the intensely competitive anti-obesity drug space. Viking's pipeline may contain plenty of hidden value that a larger company might release.

CRISPR Therapeutics and Viking Therapeutics are innovative biotechs with attractive pipelines. Both could see their shares soar as they make consistent clinical and regulatory progress.

Investment strategist Shay Boloor has outlined ten sub-$10 billion market-cap companies he believes are positioned to benefit from powerful long-term trends heading into 2026.

Together, these stocks offer you a balanced mix of growth and safety. These companies span a number of industries, and many are leaders in their markets.

The best-performing stock on this list is up just 4% this year. Investors may be undervaluing these companies' growth opportunities.

Viking Therapeutics is positioned for a pivotal 2026, advancing both injectable and oral VK2735 in obesity, with pipeline depth from an emerging amylin agonist program. VKTX's oral VK2735 has demonstrated unmatched double-digit weight loss in 13 weeks, potentially establishing leadership in the oral obesity drug segment. Despite a robust $714M cash position and a 4/5 conviction rating, risks in...

Biotech stocks and research shares diverged Thursday after reports suggested the FDA will soon require just one pivotal study.